Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
American Journal of Cardiology.
Times cited: 53
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with Anacetrapib in the DEFINE study.
Journal of Cardiovascular Pharmacology and Therapeutics.
Times cited: 26